labetalol has been researched along with Prostatic Neoplasms in 1 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wlodarczyk, N | 1 |
| Le Broc-Ryckewaert, D | 1 |
| Gilleron, P | 1 |
| Lemoine, A | 1 |
| Farce, A | 1 |
| Chavatte, P | 1 |
| Dubois, J | 1 |
| Pommery, N | 1 |
| Hénichart, JP | 1 |
| Furman, C | 1 |
| Millet, R | 1 |
1 other study available for labetalol and Prostatic Neoplasms
| Article | Year |
|---|---|
Potent farnesyltransferase inhibitors with 1,4-diazepane scaffolds as novel destabilizing microtubule agents in hormone-resistant prostate cancer.
Topics: Androgen Antagonists; Azepines; Cell Line; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screeni | 2011 |